相关实验视频

Updated: Jun 11, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

在临床前对Prolgolimab,Pembrolizumab和Nivolumab进行比较

Aleksandr Gordeev¹, Andrei Vaal², Maria Puchkova²

¹JSC BIOCAD, St.-Petersburg, Russia. gordeevaa@biocad.ru.

Scientific reports

|October 4, 2024

概括

在临床前模型中,Prolgolimab是一种IgG1抗PD-1抗体,与尼沃卢马布和潘布罗利祖马布等IgG4抗体相比,显示出更高的疗效和T细胞激活. 需要进一步进行临床比较.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

抗PD-1抗体在癌症免疫治疗中至关重要.
不同的抗体同型 (IgG1,IgG4) 可能会影响治疗疗效.
普罗戈利马布是一种工程IgG1抗PD-1抗体,具有潜在的治疗优势.

研究的目的:

为了比较prolgolimab (IgG1) 与nivolumab和pembrolizumab (IgG4) 的临床前抗原结合和效应器功能.
在小鼠癌症模型中评估prolgolimab的体内疗效.

主要方法:

对抗体依赖细胞细胞毒性 (ADCC) 和细胞细胞症 (ADCP) 的比较分析.
评估PD-1受体占用率和T细胞激活.
在体内使用CT26.wt小鼠癌细胞的疗效研究.

主要成果:

对于任何抗体,没有观察到不良的ADCC活性.
普罗戈利马布显示了较高的PD-1受体占用率和T细胞激活.
与尼沃卢马布和潘布罗利祖马布相比,prolgolimab的ADCP倾向性较低.
在体内,prolgolimab实现了56%的瘤生长抑制,而pembrolizumab则达到16%.

结论:

像prolgolimab这样的工程IgG1抗PD-1抗体可能比IgG4对应物提供更强大的治疗效益.
临床前数据支持对基于IgG1的抗PD-1抗体用于癌症治疗的临床研究.
由于Prolgolimab的功能状况得到了改善,因此可以直接与现有的IgG4抗PD-1疗法进行临床比较.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.